This spotlight audit builds on the core National Paediatric Diabetes Audit (NPDA) and looks in detail at the care processes, treatment, and comorbidities of children and young people living with Type 2 diabetes. Some of this reached beyond the scope of the NICE guidelines for the diagnosis and management of Type 1 and Type 2 diabetes. Published in April 2025.
Key Messages:
-
The number of CYP with Type 2 diabetes receiving care from a PDU in England and Wales has increased by 88%, from 810 in 2019/20, to 1,521 in 2023/24.
-
CYP with Type 2 diabetes are more likely to come from ethnic minority backgrounds or live in more deprived areas, compared to CYP with Type 1 diabetes and the general population.
-
41% of CYP with Type 2 diabetes, aged 12 or older had all six key health checks in 2023/24, compared to 66% of CYP with Type 1 diabetes. The national (England and Wales combined) median HbA1c for CYP with Type 2 diabetes in 2023/24 is 50.0 mmol/mol, compared to 52.5 mmol/mol seen in 2019/20. This is lower than that seen in Type 1 diabetes at 60.0 mmol/mol.
-
Despite the median Hba1c being lower in CYP with Type 2 diabetes compared to those with Type 1, abnormalities in both microvascular (albuminuria) and macrovascular (BMI, blood pressure, hyperlipidaemia) outcomes are more prevalent in Type 2 diabetes.
-
24% of CYP with Type 2 diabetes received psychological support in 2023/24, while an additional 29% were offered, but did not receive, psychological support. 73% received dietetic support in 2023/24.